Clinical trials: Advanced Intestinal Cancer
Colorectal Cancer
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways.
- Trial name
- NCT00940316
- Testing
- panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Small Bowel Cancers, Colorectal Cancers
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
Background: Metastatic or refractory/recurrent small bowel and colorectal cancers cannot be cured and are often not helped by standard treatments. Researchers want to find better treatments by testing a combination of drugs.
- Trial name
- NCT04491955
- Testing
- CV301, MSB0011359C, N-803
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
The purpose of this study is to find out how effective this combination is as a second line treatment for colorectal cancer that has spread from one part of the body to another (metastasized) or has not metastasized but is…
- Trial name
- NCT00574171
- Testing
- lapatinib, Capecitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Neoplasms, Colorectal Neoplasms
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)
The purpose of this study is to evaluate the safety and preliminary efficacy of MK-1697. There are 2 parts in this study: dose escalation to determine the recommended phase 2 dose (RP2D) and confirm the RP2D (Part A) and cohort…
- Conditions
- Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT03515824
- Testing
- MK-1697
- Where
- 2 sites in Australia, Hong Kong
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Melanoma (Skin), Melanoma
Pembrolizumab and EDP1503 in Advanced Melanoma
This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma.
- Trial name
- NCT03595683
- Testing
- Pembrolizumab, EDP1503
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Chicago
Colorectal Cancer
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type…
- Trial name
- PARADIGM (NCT02394795)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Where
- 155 sites in Japan
- Volunteers
- 823 people
- Sponsor
- Takeda
Rectal Cancer
A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
This study will assess the efficacy and safety of two different neoadjuvant treatment approaches including bevacizumab in newly diagnosed participants with high risk locally advanced rectal cancer.
- Trial name
- INOVA (NCT00865189)
- Testing
- Bevacizumab, Oxaliplatin, Folinic Acid
- Where
- 40 sites in France
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
Colorectal Carcinoma
BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
The purpose of this study is to find out whether it is better to receive a new drug, BBI608, or better to receive no further treatment for colon or rectal cancer.
- Trial name
- NCT01830621
- Testing
- BBI608, Best Supportive Care
- Where
- 63 sites in Australia, Canada and 1 more
- Volunteers
- 282 people
- Sponsor
- NCIC Clinical Trials Group
Advanced Cancers
Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer
The goal of this clinical research study is to learn if Lipitor (atorvastatin) or fish oil supplements can help to control side effects of the heart that are commonly seen after lung surgery (such as irregular heartbeat).
- Trial name
- NCT01259284
- Testing
- Atorvastatin, Fish Oil Supplement
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Colorectal Neoplasms
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients…
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- NCT05678257
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan
- Where
- 59 sites in United States, France and 4 more
- Volunteers
- 180 people
- Sponsor
- NuCana plc
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Colorectal Cancer
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. This study is being done to find out how long it takes tumors to grow after patients receive the drugs capecitabine…
- Trial name
- NCT00159432
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Southern California
Neoplasm, Rectum
Appropriate Timing of Surgery After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
This study aimed to compare the outcomes of early versus late surgical resection in patients who underwent curative total mesorectal excision after neoadjuvant chemoradiation.
- Trial name
- NCT03287843
- Testing
- Total mesorectal excision before 56 days (4-8 weeks), Total mesorectal excision after 56 days (8-12 weeks)
- Volunteers
- 350 people
- Sponsor
- Ege University
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Rectal Cancer, Adenocarcinoma of the Rectum
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information…
- Trial name
- NCT00307736
- Testing
- 5-fluorouracil, bevacizumab, erlotinib
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital